<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01464281</url>
  </required_header>
  <id_info>
    <org_study_id>ML27928</org_study_id>
    <nct_id>NCT01464281</nct_id>
  </id_info>
  <brief_title>A Study of Switch From Nucleotide to Peginterferon Alfa-2a in CHB Patients Achieving HBeAg Loss and HBV DNA &lt;200IU/ml</brief_title>
  <acronym>New Switch</acronym>
  <official_title>A Randomized, Multicenter Study Evaluating HBsAg Clearance in CHB Patients Achieving HBeAg Loss and HBV DNA &lt;200copies/ml on Treatment With Nucleotide Analogues and Switched to Peginterferon Alfa-2a</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Second Affiliated Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Second Affiliated Hospital of Chongqing Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, open-label, multicenter study.&#xD;
&#xD;
      The patients after 1-3 years NAs treatment and having achieved HBeAg loss and HBV DNA&#xD;
      &lt;200IU/ml will be switched to Pegasys for 48 or 96 weeks (with a 12 weeks period of overlap&#xD;
      with the NA for safety reasons). The subjects will be randomized into 2 groups:&#xD;
&#xD;
      Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week&#xD;
      prolonged treatment by Peginterferon alfa 2a 180µg/week.&#xD;
&#xD;
      All the patients will be followed up for 48 weeks after discontinuation of the study&#xD;
      medication.&#xD;
&#xD;
      Note: NAs will be stratified LAM, ETV and ADV, with the ratio 1:1:1.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      eligibility criteria: Men and women old of 18 to 65 years with chronic hepatitis B HBeAg&#xD;
      positive treated with nucleoside and/or nucleotide analogues for 1-2 years and with partial&#xD;
      response (HBeAg loss and HBV DNA &lt;1000copies/ml).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine the response rate (HBsAg clearance at Week 48 and 96)</measure>
    <time_frame>1 year</time_frame>
    <description>To determine the response rate (HBsAg clearance at Week 48 and 96) in subjects who are being treated by NAs and achieved a combined response which consists of both HBeAg loss and HBV DNA &lt;1000 copies/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBsAg/HBeAg/HBV DNA changes/ALT normalization /HBsAg seroconversion at EOT and EOF</measure>
    <time_frame>1 year</time_frame>
    <description>HBsAg loss at EOF&#xD;
Quantitative HBe/sAg reduction at every check point.&#xD;
HBeAg seroconversion at EOT and EOF&#xD;
HBV DNA changes over 48 or 96 weeks at every check points&#xD;
ALT normalization at EOT and EOF&#xD;
HBsAg seroconversion at EOT and EOF</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>48-week standard treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>48-week standard treatment by Peginterferon alfa 2a 180µg/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>96-week prolonged treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>96-week prolonged treatment by Peginterferon alfa 2a 180µg/week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa 2a</intervention_name>
    <description>Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.</description>
    <arm_group_label>48-week standard treatment</arm_group_label>
    <arm_group_label>96-week prolonged treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients on-treatment with NAs (ADV, ETV or LAM) for 1-3 years, having achieved HBeAg&#xD;
             loss at screening, and HBV DNA &lt;200IU/ml for at least 48 weeks&#xD;
&#xD;
          -  Male and female patients ≥ 18 to 65 years of age&#xD;
&#xD;
          -  Chronic hepatitis B (positive HBsAg for at least 6 months prior to NA therapy start)&#xD;
&#xD;
          -  Compensated liver disease (Child-Pugh &lt;6)&#xD;
&#xD;
          -  Absence of hepatocellular carcinoma on liver imaging and/or alfa fetoprotein &lt; 50&#xD;
             ng/ml&#xD;
&#xD;
          -  Negative urine or blood pregnancy test for women of childbearing potential within 24&#xD;
             hours of first PEG IFN study medication administration&#xD;
&#xD;
          -  Able and willing to provide informed consent and abide by the requirements of the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Neutrophil count &lt;1.5 x 109cells/L or platelet count &lt;90 x 109cells/L&#xD;
&#xD;
          -  Co-infections with HIV, HAV, HCV, HDV or HEV&#xD;
&#xD;
          -  Women with ongoing pregnancy or breast feeding, or wishing to become pregnant during&#xD;
             the study period&#xD;
&#xD;
          -  Prolonged and excessive alcohol intake (&gt; 40g/day for men and &gt; 30g/day for women)&#xD;
&#xD;
          -  Active intravenous drug abuse&#xD;
&#xD;
          -  History or current treatment with telbivudine&#xD;
&#xD;
          -  Treatment with immunomodulators (e.g. Interferon) for less than one year before study&#xD;
             enrollment&#xD;
&#xD;
          -  Treatment with immunosuppressors (including systemic corticosteroids) or&#xD;
             anti-neoplastic treatment (including radiation therapy) &lt;=6 months prior to the first&#xD;
             dose of study drug or the expectation that such treatment will be needed at any time&#xD;
             during the study&#xD;
&#xD;
          -  Serum concentrations of ceruloplasmin or alfa-antitrypsin consistent with an increased&#xD;
             risk of metabolic disease&#xD;
&#xD;
          -  History or other evidence of chronic pulmonary disease associated with functional&#xD;
             limitation&#xD;
&#xD;
          -  History of severe cardiac disease&#xD;
&#xD;
          -  History of the severe seizure disorder or current anticonvulsivant use&#xD;
&#xD;
          -  History of thyroid disease poorly controlled on prescribed medications. Patients with&#xD;
             elevated thyroid stimulating hormone concentrations with elevation of antibodies to&#xD;
             thyroid peroxidase and any clinical manifestations of thyroid disease&#xD;
&#xD;
          -  History or other evidence of severe retinopathy&#xD;
&#xD;
          -  History of autoimmune disease or presence of a significant level of auto-antibodies&#xD;
&#xD;
          -  Renal insufficiency (creatinine clearance of &lt; 50 ml/min according to the Cockroft and&#xD;
             Gault equation), kidney transplant, hemodialysis&#xD;
&#xD;
          -  History of depression or uncontrolled psychiatric disorders&#xD;
&#xD;
          -  Subjects protected by law or not in a position to give consent&#xD;
&#xD;
          -  Patients with reproductive potential not willing to use an effective method of&#xD;
             contraception.&#xD;
&#xD;
          -  Evidence of an active or suspected cancer or a history of malignancy (other than&#xD;
             basocellular carcinoma or in-situ cervical carcinoma)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hong Ren</last_name>
    <role>Principal Investigator</role>
    <affiliation>The 2nd affiliated Hospital of Chongqing Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The 2nd affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <study_first_submitted>October 19, 2011</study_first_submitted>
  <study_first_submitted_qc>November 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2011</study_first_posted>
  <last_update_submitted>November 1, 2011</last_update_submitted>
  <last_update_submitted_qc>November 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Second Affiliated Hospital of Chongqing Medical University</investigator_affiliation>
    <investigator_full_name>Hong Ren</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>nucleoside</keyword>
  <keyword>peginterferon alfa-2a</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

